Business · Companies · 7 hrs ago
Mesoblast shifts from research to selling its first therapy
Mesoblast is shifting from research to commercial sales after more than two decades of development and setbacks.
The Australia-based stem-cell company began selling Ryoncil in the United States in late 2025, after the FDA approved it in late 2024 to treat paediatric graft-versus-host disease.
Ryoncil brought in US$115 million in sales in the 2025-26 year.
The company reported US$1.068 billion in accumulated losses as of June, showing the scale of its investment and financial challenges.
Mesoblast is testing other potential treatments, including rexlemestrocel-L for chronic low back pain and a trial to extend Ryoncil’s use to adults.
The company has completed enrolment in the pivotal phase III back-pain study and begun enrolling patients in the adult Ryoncil trial.
Its next challenge is turning scientific progress into sustained commercial success.
Mesoblast has shifted from a research-focused company to selling its first therapy, Ryoncil.
The US Food and Drug Administration approved Ryoncil in late 2024, and sales began in late 2025.
The therapy generated US$115 million in sales in the 2025-26 year.
Chairman Phil Facchina said the change requires the company to focus increasingly on commercial execution.
Mesoblast has completed enrolment in a pivotal phase III trial of rexlemestrocel-L for chronic low back pain and begun enrolment in a trial to expand Ryoncil to adults.
- Who
- Mesoblast, an Australian stem-cell developer.
- What
- The company is shifting from research and development towards commercial sales, led by its first therapy, Ryoncil.
- When
- It began selling Ryoncil in late 2025. The article was published on 10 November 2026.
- Where
- The United States; the FDA approved Ryoncil and the company began selling it there.
- Why
- Mesoblast is moving to commercial execution after Ryoncil’s approval and launch. Facchina said the transition is an opportunity and a fundamental change in how the company operates.
This story does not have two clearly opposing sides.
The US Food and Drug Administration approved Ryoncil.
Mesoblast began selling Ryoncil.
Ryoncil generated US$115 million in sales.
Stockhead reported Facchina’s remarks at Mesoblast’s annual general meeting.
- First product
- Ryoncil, a paediatric graft-versus-host disease treatment
- FDA approval
- Late 2024
- Sales launch
- Late 2025
- 2025-26 sales
- US$115 million
- Chronic low back pain trial
- Enrolment completed for the pivotal phase III study of rexlemestrocel-L
- Adult Ryoncil trial
- Enrolment has started for the registrational trial to expand treatment to adults
What people are saying
We are transitioning from a company whose value had been driven exclusively by its scientific progress and the potential of its clinical pipeline to one that must increasingly be focused on commercial execution.
This transition represents both an extraordinary opportunity and a fundamental change in how Mesoblast operates, executes and measures its success.